Meeting Overview



As the pharmaceutical and biotech industries face pending healthcare and biologics legislation, the future of the industry remains in flux. Many companies have generics coming off patent necessitating discussion on new investments, pipeline issues and increased research & development.

These are amongst the topics that will be addressed on June 16th, when Argyle Executive Forum will host its Leadership in Pharmaceuticals and Biotechnology meeting, taking place in Manhattan.

This event will feature insights from top executives, including:

Speaker
Mark Altmeyer President and Chief Executive Officer
Otsuka America Pharmaceutical, Inc.
View Bio »
Speaker
Linda Bowers VP Life Sciences Product Marketing
IntraLinks
View Bio »
Speaker
Sean Brynjelsen Vice President, Business Development and R&D
Akorn, Inc.
View Bio »
Speaker
Carol Cruickshank Vice President and Partner
A.T. Kearney
View Bio »
Speaker
Matt Cushing Partner
Bingham McCutchen
View Bio »
Speaker
David H. Donabedian, PhD, MBA Vice President, Global New Deal Strategy & Development
US CEEDD, GSK
View Bio »
Speaker
Dimitri Drone Partner
PwC
View Bio »
Speaker
Chris Garabedian President & CEO, AVI BioPharma and
Former Vice President, Corporate Strategy, Celgene
View Bio »
Speaker
Adam Golden Partner
Kaye Scholer
View Bio »
Speaker
Keith M. Gottesdiener, M.D. Vice President, Development
Merck & Co., Inc.
View Bio »
Speaker
Milton Grannatt Vice President & Head, Negotiations, Respiratory & New Growth Opportunities Global Business Development & Licensing
Novartis Pharmaceuticals Corporation
View Bio »
Speaker
William Hoffman Partner
Kaye Scholer LLP
View Bio »
Speaker
Sharon Kochan Executive Vice President, U.S. Generics
Perrigo Company
View Bio »
Speaker
Jeff Levy Director, Business Development
RR Donnelley
View Bio »
Speaker
Michael Mentesana US Pharmaceutical and Life Sciences R&D Advisory Services Leader
PwC
View Bio »
Speaker
Polly Murphy VP, R&D Business Development
Pfizer Inc.
View Bio »
Speaker
Adelene Q. Perkins President and Chief Executive Officer
Infinity Pharmaceuticals, Inc.
View Bio »
Speaker
Marla S. Persky Senior Vice President, General Counsel and Secretary
Boehringer Ingelheim USA Corporation
View Bio »
Speaker
Barry Ticho, M.D., Ph.D. Vice President, R&D
Biogen Idec
View Bio »
Speaker
Pol Vandenbroucke Vice President, Clinical Development, Emerging Markets Business Unit
Pfizer
View Bio »
Speaker
Greg Wiederrecht, PhD, CLP Vice President & Head, External Scientific Affairs Worldwide Licensing & External Research
Merck & Co., Inc.
View Bio »
Speaker
Michael Wise Partner
A.T. Kearney
View Bio »
Speaker
Brett Zbar Partner
Aisling Capital
View Bio »
  • 8:00am – 9:00am Breakfast
  • 9:00am – 9:10am Argyle Executive Forum Opening Remarks
  • 9:10am – 9:40am “Nightmares from the Pillows of General Counsels”
    read more »

    Marla S. PerskySenior Vice President, General Counsel and Secretary Boehringer Ingelheim USA CorporationInterviewed By:William HoffmanPartnerKaye Scholer LLP

  • 9:45am – 10:35am Panel Discussion Presented by PwC
    read more »

    "The Environment for New Drug Development”

    • How can we drive more new and innovative drugs in large pharmaceutical companies?
    • What impact does consolidation in the industry have on new drug development?
    • It seems that the era of 'the blockbuster drug' is waning. Yet the cost to bring a compound to market continues to increase. Can we find less expensive ways to bring drugs to market?
    • Do you see private equity firms (including VCs) playing a more prominent role in funding R&D activities in the future?
    • What changes are occurring in assessing the economic returns of a potential drug candidate?
    • In house discovery vs. in-licensing and strategic alliances – the pros and cons of both methods in identifying new drug candidate
    • As developing countries mature, they will require extensive pharmaceutical and healthcare development and investment. Thoughts on opportunities cross border and abroad?
    Moderator:Dimitri DronePartnerPwCPanelists:Mark AltmeyerPresident and Chief Executive OfficerOtsuka America Pharmaceutical, Inc.Sean BrynjelsenVice President, Business Development and R&DAkorn, Inc.Michael MentesanaUS Pharmaceutical and Life Sciences R&D Advisory Services LeaderPwCBarry Ticho, M.D., Ph.D.Vice President, R&DBiogen IdecPol Vandenbroucke Vice President, Development, Emerging Markets Business UnitPfizer

  • 10:40am – 11:00am A.T. Kearney Thought Leadership Spotlight
    read more »

    "Transforming the Pharma Industry to meet the Challenges of the New Decade"

    • Un-precedent challenges are requiring the industry to transform how they do business
    • Fundamental changes in the operating model
    • Generating value from M&A
    Carol CruickshankVice President and PartnerA.T. Kearney

    and

    Michael WisePartnerA.T. Kearney

  • 11:00am -11:30am Coffee Break
  • 11:30am – 12:20pm Panel Discussion
    read more »

    “Leadership in Pharmaceuticals & Biotechnology”

    • The R&D Model- what’s working, what isn’t and the future of R&D in the life science space
    • The impact of healthcare reform on the pharmaceutical & biotech industry
    • What is the role of the pharmaceutical industry in healthcare reform?
    • Life cycle management issues: managing early, time to market pressure and the cost/benefit of follow-on drugs.
    • Drug portfolio diversification- how can we avoid putting “all of our eggs in one basket”?
    Moderator:Matt CushingPartnerBingham McCutchen Panelists:David H. Donabedian, PhD, MBAVice President, Global New Deal Strategy & DevelopmentUS CEEDD, GSKKeith M. Gottesdiener, M.D.Vice President, DevelopmentMerck & Co., Inc.Adelene PerkinsPresident and Chief Executive Officer Infinity Pharmaceuticals, Inc.*This session is Off the Record

  • 12:20pm - 12:25pm Introducing Chris Garabedian:
    read more »

    Jeff LevyDirector, Business DevelopmentRR Donnelley

  • 12:25pm – 12:55pm "Biotech Business Models"
    read more »

    Perspectives on valuations, business development strategies, and the role of biotech in pharma's business model.

    Chris GarabedianPresident & CEO, AVI BioPharma andFormer Vice President, Corporate Strategy, Celgene

  • 12:55pm – 1:55pm Lunch
  • 1:55pm – 2:45pm Panel Discussion
    read more »

    “Deal Making in Pharmaceuticals & Biotechnology”

    Session Topics include but are not limited to:

    • How will economic recovery play a role in pharmaceutical M&A? Why are deal makers expecting things to heat up in 2011?
    • What are the key factors for valuing a deal in today’s Pharmaceutical & Biotech markets?
    • Looking at values from a costs and risks perspective
    • Which therapeutic areas pose the best opportunity for deals?
    • What deal structure is going to work given the changing regulatory landscape?
    • Drivers behind a particular deal structure
    • Alliances
    • JV’s
    • Acquisitions
    • Mergers
    Moderator:Adam GoldenPartnerKaye ScholerPanelists:David H. Donabedian, PhD, MBAVice President, Global New Deal Strategy & DevelopmentUS CEEDD, GSKMilton GrannattVice President & Head, Negotiations, Respiratory & New Growth Opportunities Global Business Development & LicensingNovartis Pharmaceuticals CorporationPolly MurphyVP, R&D Business DevelopmentPfizer Inc. Brett ZbarPartnerAisling Capital*This session is Off the Record

  • 2:45pm - 2:50pm Introducing Greg Wiederrecht, PhD, CLP:
    read more »

    Linda BowersVP Life Sciences Product MarketingIntraLinks

  • 2:50pm – 3:20pm "Merck's Perspective on Working with External Partners and How it Fits into Our R&D Process"
    read more »

    Greg Wiederrecht, PhD, CLPVice President & Head, External Scientific Affairs Worldwide Licensing & External ResearchMerck & Co., Inc.*This session is Off the Record

  • 3:25pm – 3:55pm “Perrigo’s Perspective on the US Generic Market”
    read more »

    Sharon KochanExecutive Vice President, U.S. GenericsPerrigo Company

  • 3:55pm – 4:00pm Argyle Executive Forum Closing Remarks
  • 4:00pm – 5:00pm Closing Reception
    read more »

    *Agenda is subject to change

Still have questions? We have answers.

I want to attend, but what if I'm unsure of my schedule and need to cancel my participation?

Just let us know. We understand that schedules change! However, we always have a waiting list for this event, and if you don't cancel, we will assume you are still attending and your spot will go unused. If you must, cancel at least 48 hours prior to the event to make room for others!

What if I can't be OOO for a whole day, or need to come late?

We have wifi and private rooms available for attendees to take calls and spend some quiet time on emails, as well as access to printing. Have a morning meeting you can't miss? No problem. This event was designed for busy executives - we get it.

I'd like to bring some colleagues. Do I need to register them online?

Events are more fun with friends, and we'd be happy to host your team. You can have them register online, or send us their names, titles and email addresses and we will take care of it for you!

I don't see the event venue listed. Where will the meeting be held?

To maintain exclusivity, we don't release the venue address until the registration process has been completed. All logistical details will be shared once you have requested a pass and been approved.

The 2011 Leadership in Pharmaceuticals & Biotechnology in New York
is proudly sponsored by:

Traveling for the event? Stay at one of our recommended hotels nearby:

Venue

Algonquin Hotel

59 West 44th Street
New York, NY 10039
Telephone: (212) 840-6800
Website

Venue

Iroquois Hotel

49 West 44th Street
New York, NY 10039
Telephone: (212) 977-2719
Website

Venue

Mansfield Hotel

12 West 44th Street
New York, NY 10039
Telephone: (212) 944-6050
Website

Venue

Millennium Broadway

145 West 44th Street
New York, NY 10039
Telephone: (212) 768-4400
Website

Venue

Royalton Hotel

44 West 44th Street
New York, NY 10039
Telephone: (212) 869-4400
Website

Venue

Sofitel

45 West 44th Street
New York, NY 10039
Telephone: (212) 354-8844
Website